

Scancell

Fundraise extends cash into H226 beyond key catalysts

6 December 2024

- Scancell has raised c £10.3m (gross) through an oversubscribed Placing (to new and existing institutional shareholders) and Subscription, with a total of 97,467,141 new shares to be issued. The issue price for the fundraise is 10.5p. An additional up to £1m may also be raised through a Retail Offer to all qualifying shareholders, which will close on 9 December. New shares are expected to be admitted to trading on 10 December. The fundraise extends Scancell's runway beyond key clinical data outcomes, including for SCIB1/iSCIB1+ and Modi-1 (more details below), and will allow Scancell to explore potential partnering/out-licencing from a position of strength.
- The Phase II [SCOPE](#) study of SCIB1/iSCIB1+ in combination with standard-of-care doublet therapy (ipilimumab and nivolumab) in advanced melanoma is ongoing, with further data expected during 2025. Recent initial data from Cohort 1 (SCIB1 with doublet therapy, which has recruited 42 of the planned 43 patients) demonstrated an objective response rate (ORR) of 72% at 25 weeks, based on 25 evaluable patients, exceeding the 48% ORR seen with doublet therapy ([November 2024 Lighthouse](#)). Cohort 3 is examining next generation iSCIB1+ and has recruited 33 of the planned 43 patients; this is examining iSCIB1+ delivered into the muscle (intramuscular, IM). Cohort 4 is also being added to the study to examine iSCIB1+ delivered into the skin (intradermal, ID), which could make the vaccine more efficient given the large number of antigen-presenting cells that are in the skin.
- The Phase I/II [ModiFY](#) trial of Modi-1 as monotherapy and in combination with checkpoint inhibitors (CPIs) in various challenging solid tumours is ongoing. Enrolment in the arm exploring Modi-1 with CPIs in advanced renal cell carcinoma (RCC) is underway, aiming to recruit 44 untreated patients.
- The new funds, together with existing cash (£9.1m on 1 November), and anticipated receipt of a mid-single digit \$m milestone from Genmab for the second GlyMab deal ([December 2024 Lighthouse](#)) will provide Scancell with a cash runway through to H226. This is beyond the following key clinical milestones: (1) full SCIB1 Cohort 1 ORR data from 43 patients in H125; (2) Modi-1 RCC CPI combination data in H125; (3) iSCIB1+ Cohort 3 IM data in H225; and (4) initial iSCIB1+ Cohort 4 ID data in H225.

Trinity Delta view: Scancell's upsized £10.3m fundraise, including to new specialist healthcare investors, extends the cash runway to H226, beyond key value inflection points for both SCIB1/iSCIB1+ and Modi-1, and also allows the time for Scancell to evaluate potential suitable out-licencing and partnering opportunities to optimally advance key assets from a position of strength. The fundraise reflects continued momentum at Scancell, with recent positive SCIB1 data, and hot on the heels of the second GlyMab deal with Genmab. As the prospects for the pipeline become clearer over the next 12-18 months, this should unlock value within Scancell that is currently underappreciated, in our view. As usual in such situations, we suspend our valuation and forecasts; for context our last published rNPV based valuation for Scancell was £311m.

Price	11.13p
Market Cap	£125.5m
Primary exchange	AIM
Sector	Healthcare
Company Code	SCLP
Corporate client	Yes

Company description:

Scancell is a clinical-stage immuno-oncology specialist that has four broadly applicable technology platforms. Two are therapeutic vaccines, Moditope and ImmunoBody, and two are antibody based, GlyMab and AvidiMab.

Analysts

Lala Gregorek

lgregorek@trinitydelta.org
+44 (0) 20 3637 5043

Philippa Gardner

pgardner@trinitydelta.org
+44 (0) 20 3637 5042

Philippa Gardner

pgardner@trinitydelta.org

+44 (0) 20 3637 5042

Lala Gregorek

lgregorek@trinitydelta.org

+44 (0) 20 3637 5043

Franc Gregori

fgregori@trinitydelta.org

+44 (0) 20 3637 5041

Disclaimer

Trinity Delta Research Limited ("TDRL"; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited ("ED"). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is not deemed to be independent, as defined by the FCA, but is 'objective' in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2024 Trinity Delta Research Limited. All rights reserved.

More information is available on our website: www.trinitydelta.org